Multisystem Imaging Manifestations of COVID-19, Part 1: Viral Pathogenesis and Pulmonary and Vascular System Complications

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in coronavirus disease 2019 (COVID-19), which was declared an official pandemic by the World Health Organization on March 11, 2020. The infection has been reported in most countries around the world. As of August 2020, there have been over 21 million cases of COVID-19 reported worldwide, with over 800,000 COVID-19–associated deaths. It has become apparent that although COVID-19 predominantly affects the respiratory system, many other organ systems can also be involved. Imaging plays an essential role in the diagnosis of all manifestations of the disease, as well as its related complications, and proper utilization and interpretation of imaging examinations is crucial. With the growing global COVID-19 outbreak, a comprehensive understanding of the diagnostic imaging hallmarks, imaging features, multisystemic involvement, and evolution of imaging findings is essential for effective patient management and treatment. To date, only a few articles have been published that comprehensively describe the multisystemic imaging manifestations of COVID-19. The authors provide an inclusive system-by-system image-based review of this life-threatening and rapidly spreading infection. Part 1 of this article, the authors discuss general aspects of the disease, with an emphasis on virology, the pathophysiology of the virus, and clinical presentation of the disease. The key imaging features of the varied pathologic manifestations of this infection that involve the pulmonary and peripheral and central vascular systems are also described. Part 2 will focus on key imaging features of COVID-19 that involve the cardiac, neurologic, abdominal, dermatologic and ocular, and musculoskeletal systems, as well as pediatric and pregnancy-related manifestations of the virus. Vascular complications pertinent to each system will also be discussed in part 2.

Online supplemental material is available for this article.

©RSNA, 2020 • radiographics.rsna.org

SA-CME LEARNING OBJECTIVES

After completing this journal-based SA-CME activity, participants will be able to:

- Describe the pathophysiology and clinical presentation of SARS-CoV-2, as well as its effects on the immune system and coagulatory pathway.
- Discuss the most appropriate imaging modalities and current radiologic recommendations for the diagnosis of pulmonary and vascular manifestations of COVID-19 and their related complications.
- Recognize key imaging features of the pulmonary and peripheral and central vascular manifestations of COVID-19, as well as their complications.

See rsna.org/learning-center-rg.
Respiratory illness is the most commonly associated manifestation of SARS-CoV-2. This is due to abundant ACE2 receptor expression in the lung parenchyma, specifically on the acinar side of lung epithelial cells (pneumocytes) within the alveolar spaces, allowing virus entry. This correlates with the observation that the earliest lung injury is often seen in the distal airways.

Chest radiography and chest CT may be performed as adjuncts in cases of an initial negative RT-PCR test with persistent high clinical suspicion for disease.

Similar to those at chest radiography, the most suspicious CT features for COVID-19 infection in the lungs include multifocal bilateral peripheral GGOs, with or without focal consolidations, in lung regions close to pleural surfaces, including the fissures.

Patients admitted to the ICU with barotrauma as a result of intubation or as a complication of ARDS may develop pneumothoraces or pneumomediastinum, further complicating the pulmonary manifestations of COVID-19 infection.

There is growing evidence of coagulopathy related to COVID-19, which may predispose patients to both venous and arterial thromboembolism and result in DVT, PE, limb ischemia, stroke, and myocardial infarction. Although the pathogenesis and incidence of thrombotic complications are not clearly understood, coagulopathy has been noted to be a poor prognostic indicator and is associated with higher mortality.

TEACHING POINTS

- Respiratory illness is the most commonly associated manifestation of SARS-CoV-2. This is due to abundant ACE2 receptor expression in the lung parenchyma, specifically on the acinar side of lung epithelial cells (pneumocytes) within the alveolar spaces, allowing virus entry. This correlates with the observation that the earliest lung injury is often seen in the distal airways.
- Chest radiography and chest CT may be performed as adjuncts in cases of an initial negative RT-PCR test with persistent high clinical suspicion for disease.
- Similar to those at chest radiography, the most suspicious CT features for COVID-19 infection in the lungs include multifocal bilateral peripheral GGOs, with or without focal consolidations, in lung regions close to pleural surfaces, including the fissures.
- Patients admitted to the ICU with barotrauma as a result of intubation or as a complication of ARDS may develop pneumothoraces or pneumomediastinum, further complicating the pulmonary manifestations of COVID-19 infection.
- There is growing evidence of coagulopathy related to COVID-19, which may predispose patients to both venous and arterial thromboembolism and result in DVT, PE, limb ischemia, stroke, and myocardial infarction. Although the pathogenesis and incidence of thrombotic complications are not clearly understood, coagulopathy has been noted to be a poor prognostic indicator and is associated with higher mortality.

Introduction

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei province of China. In the first few months of 2020, infection with this novel coronavirus led to a global pandemic that has now affected almost every country in the world, and, by August 2020, over 21 million cases had been documented (1,2). Although SARS-CoV-2 disease (or coronavirus disease 2019 [COVID-19]) primarily manifests as a lung infection, with symptoms ranging from those of a mild upper respiratory infection to severe pneumonia and acute respiratory distress syndrome (ARDS), other multisystemic manifestations of this disease and related complications are becoming more commonly recognized (3).

In this article, we provide an inclusive review of this potentially life-threatening and highly contagious infection, with emphasis on clinical presentation, the pathophysiology of the virus, and the role of imaging in diagnosing and monitoring the viral infection and its related complications. We provide a system-by-system review of the key imaging features of the various pathologic manifestations known to date, as well as offer relevant prognostic information that can be inferred from imaging findings. In part 1 of this article, we discuss general aspects of the disease, with an emphasis on virology, the pathophysiology of the virus, and clinical presentation of the disease. In addition, we describe in detail the key imaging features of the varied pathologic manifestations of this infection that involve the pulmonary and peripheral and central vascular systems.

All medical professionals, including radiologists, have been given the daunting task of recognizing the varied presentations and complications of COVID-19 to ensure prompt diagnosis and thereby limit viral spread, as well as provide appropriate care to patients with the goal of improving recovery.

Background

Virology

Coronaviruses are nonsegmented enveloped RNA viruses with a single-strand linear positive-sense RNA (4,5). Six types of coronavirus have been identified that cause human disease. Four of these cause mild respiratory symptoms whereas the other two, Middle East respiratory syndrome (MERS-CoV) coronavirus and severe acute respiratory syndrome coronavirus (SARS-CoV-1), have previously resulted in epidemics with high mortality rates (6). Although the genome of SARS-CoV-2 is 80% identical to that of SARS-CoV-1, it is more similar to the genome of bat coronaviruses (96% identical) (7). Both SARS-CoV-1 and SARS-CoV-2 have similar receptor-binding gene regions, thus for cell entry both viruses use the same angiotensin-converting enzyme 2 (ACE2) receptor (7). Currently, two different types of SARS-CoV-2 have been identified. However, the implications of this finding are uncertain (8).

Diagnosis

COVID-19 is generally diagnosed with the results of a real-time reverse transcription–polymerase chain reaction (RT-PCR) test of a nasopharyngeal specimen obtained with a swab. However, this test may obtain false-negative results owing to a variety of factors, including insufficient viral load, improper collection of viral samples, and technical errors during the swabbing procedure (9,10).

Epidemiology

More than 21 million confirmed cases of COVID-19 have been reported to date around the world, within all continents except for Antarctica, and the incidence has been steadily rising (11). In the United States, COVID-19 has been reported in all 50 states, the District of Columbia, and at least four territories (12). The cumulative incidence varies by state and is likely dependent on a number of factors, including population density and demographics, the extent of testing and reporting, and the initiation of mitigation strategies.

In the United States, outbreaks in long-term care facilities and homeless shelters have underscored
the risk of exposure and infection in group settings (13). The main mode of transmission is person to person. However, other sources of transmission have also been implicated (14–16). Person-to-person transmission is thought to occur mainly through respiratory droplets that are released in a cough or sneeze or during conversation. Droplets typically do not travel more than 6 ft (about 2 m) and are not thought to linger in the air, although this notion has been challenged (14–16).

Environmental contamination also plays a role in viral transmission and occurs through droplet accumulation on frequently touched surfaces, with subsequent spread to susceptible mucous membranes within the mouth, nose, and eyes (14–16). Men are disproportionately more commonly affected by an infection with SARS-CoV-2, and the in-hospital mortality rate among male patients is significantly higher compared with that of female patients (17).

**Viral Shedding and Infectivity**

There is uncertainty regarding the time interval during which an individual with COVID-19 is infectious. It appears that the virus can be transmitted before the development of symptoms and throughout the course of illness. However, definitive data are not yet available, as most information on this subject comes from studies that evaluated the presence of viral RNA in respiratory and other specimens, which may not correlate with infectivity.

Transmission of SARS-CoV-2 from asymptomatic individuals (or individuals within the incubation period) has been well documented (18–22). However, the extent to which asymptomatic and presymptomatic transmission occurs and their relative contribution to the spread of the pandemic remain unknown. The length of time an individual remains infectious is also uncertain. The duration of viral shedding is variable, and there appears to be a wide range, which may be dependent on the severity of illness (23–25).

**Mechanism of SARS-CoV-2 Invasion into Host Cells**

The life cycle of the virus within the host consists of the following five steps: (a) attachment, (b) penetration (viral entry to the cell), (c) biosynthesis (viral replication), (d) maturation (assembly and accumulation), and (e) release (through cell destruction). ACE2 has been identified as a functional receptor for SARS-CoV-2 (26). In the human body, ACE2 expression is high in the lung (expressed on lung epithelial cells), heart, gastrointestinal system, kidney, pancreas, spleen, bladder, cornea, and blood vessels (27,28). SARS-CoV-2 enters a human cell by binding its spike or S protein to the ACE2 receptor of the host, with subsequent fusion of the viral and cell membranes (endocytosis), resulting in viral cell entry and depletion of ACE2 receptors on the cell surface (29). Once within a cell, the virus activates the intracellular immune system, which causes immune and nonimmune cells to release large amounts of proinflammatory cytokines that activate a cytokine storm and result in damage to the host (30) (Fig 1).

**Immunity**

Antibodies to the virus are induced in those patients with SARS-CoV-2 infection. However, it is unknown whether all patients with SARS-CoV-2 infection mount a protective immune response and how long any protective effect will last. Preliminary data on protective immunity are beginning to emerge (31,32).

**Clinical Features**

The incubation period for COVID-19 is believed to be less than 14 days following exposure, with most cases manifesting 4–5 days after exposure (19,33–35). The clinical presentation spectrum varies and includes mild to moderate symptoms (80%), severe symptoms (14%–15%), and critical illness (5%). There is increasing evidence that many patients with COVID-19 are asymptomatic yet are able to transmit the virus to others. On the basis of data from several most recent meta-analyses, it has been estimated that approximately 15%–45% of patients with confirmed COVID-19 are asymptomatic. However, it is important to recognize that a large percentage of patients with no symptoms at the time of detection will become symptomatic later. For a more accurate estimation of patients with confirmed COVID-19 who remain asymptomatic throughout the disease course, longitudinal data must be collected over a sufficient period of time to allow distinction between asymptomatic and presymptomatic cases (36,37).

In addition, various studies have reported that children are likely to have a higher proportion of asymptomatic infection than adults. However, the largest meta-analysis and systematic review studies to date report that only approximately 17%–27.7% of confirmed pediatric cases are asymptomatic (37,38). As with the adult population, the accuracy of this reported data remains unclear, as there are significant concerns regarding potential selection bias and testing error.

The most common symptoms at presentation are fever, cough, and shortness of breath. Mild to moderate disease is generally characterized by constitutional symptoms and the possible development of mild pneumonia, while symptoms of severe disease include dyspnea and hypoxia, as well as more than 50% lung involvement at
imaging within 24–48 hours of symptom onset. Critically ill patients are diagnosed with respiratory failure, shock, or multiorgan dysfunction (39–44). Although most symptoms are respiratory in nature, clinical features of the disease may vary, with both typical and atypical presentations (Table 1). Recovery time appears to be around 2 weeks for mild infections and 3–6 weeks for severe disease (46).

Complications
The SARS-CoV-2 virus has the potential to cause complications in every body system. ARDS is a major complication of severe COVID-19, seen in 20%–40% of patients with severe symptoms, and typically develops within 6–8 days after the onset of dyspnea. Up to 12% of patients with ARDS will require mechanical ventilation (47,48). ARDS is usually seen in patients greater than 65 years of age and/or those with risk factors (discussed in the following section) (48).

Cardiac complications include arrhythmias (including atrial fibrillation), acute myocarditis, cardiomyopathy, and shock (47,49). Abdominal and/or pelvic solid organ injury is also commonly seen. Thromboembolic complications, including pulmonary embolism (PE), peripheral venous and arterial thrombosis, and acute stroke (seen also in patients older than 50 years without risk factors) have all been reported (50–57).

Impact of Age and Underlying Conditions
Individuals of any age can acquire SARS-CoV-2 infection, although adults middle-aged and older are most commonly affected, and older adults are more likely to experience severe disease (41,42,58). Older age is also associated with increased mortality (41,42,58). Eighty-seven percent of patients diagnosed with COVID-19 are 30–79 years of age (41), and 80% percent of reported deaths have occurred in those aged greater than or equal to 65 years. Children are significantly less affected and exhibit a milder spectrum of disease.

An increased risk of developing severe illness and increased mortality have been reported in patients with underlying cardiovascular disease, diabetes mellitus, hypertension, chronic lung disease, cancer (particularly hematologic malignancies, lung cancer, and metastatic disease), obesity, and chronic kidney disease (44,59–61). The Centers for Disease Control and Prevention also includes immunocompromised status and liver disease as potential risk factors for severe illness, although specific data regarding risks associated with these conditions are limited.

Laboratory Test Findings
Common laboratory test findings in those patients admitted to the hospital with COVID-19 include lymphopenia and elevated aminotransaminase, lactate dehydrogenase, and inflammatory marker

Figure 1. Illustration shows the proposed mechanism of SARS-CoV-2 cell entry and activation of the immune system. SARS-CoV-2 enters human cells by attaching to a cell surface receptor (ACE2) and by utilizing a human enzyme called transmembrane serine protease 2 (TMPRSS2). Once bound to the receptor, SARS-CoV-2 undergoes endocytosis and enters into the cell, along with the ACE2 receptor. This process reduces the number of ACE2 receptors on cells, leading to an increase of angiotensin II (AngII) levels in the blood. Angiotensin II triggers an inflammatory pathway involving NF-xB and interleukin 6–signal transducer and activator of transcription 3 protein (IL-6-STAT3), particularly in nonimmune cells including endothelial and epithelial cells. This pathway forms a positive feedback cycle, named IL-6 amplifier (IL-6 AMP), resulting in its excessive activation and therefore the cytokine storm and ARDS. Part of this pathway involving NF-xB, IL-6-STAT3, or both is enhanced with age, which could be the reason why older patients are more at risk for death following COVID-19 diagnosis compared with other age groups. S1 = viral spike protein subunit 1, S2 = viral spike protein subunit 2, TNF-a = tumor necrosis factor-a.
levels (eg, ferritin, C-reactive protein, and erythrocyte sedimentation rate) (34,62,63). Lymphopenia is particularly common and is characterized by a lymphocyte count less than 1500/microL. Up to 13% of patients have leukocytosis (>10,000/microL) and 15% of patients have leukopenia (<4000/microL) (63). In those patients who require treatment in the intensive care unit (ICU) for pneumonia and/or other multisystem manifestations, serum procalcitonin levels are more likely to be elevated (41,62). Several laboratory test features, including elevated d-dimer levels (>2.0 mg/mL) and severe lymphopenia, have been associated with higher mortality rates (Table 2) (41,45).

**Table 1: Typical and Atypical Clinical Features of COVID-19**

| Typical Features          | Occurrence (%) | Atypical Features          | Occurrence (%) |
|---------------------------|----------------|---------------------------|----------------|
| Fever                     | 88             | Neurologic                | 50             |
| Fatigue                   | 70             | Muscle pain               | 29             |
| Dry cough                 | 68             | Skin rash                 | 20             |
| Anorexia                  | 40             | Sore throat               | 17             |
| Myalgia                   | 35             | Psychiatric               | 14             |
| Dyspnea                   | 31             | Headache                  | 12             |
| Sputum production         | 27             | Rhinorrhea                | <7             |
| Anosmia and dysgeusia     | 19–34          | Chest pain                | 5–50           |
| Diarrhea                  | 10             | Pseudochilblain           | <5             |
| Abdominal pain            | 9              | Conjunctivitis            | <3             |
| Nausea and vomiting       | 4              | Guillain-Barré syndrome   | NA*            |

Source.—Reference 45.

*NA = not available.

**Table 2: Laboratory Test Results Associated with Worse Outcomes in COVID-19**

| Findings                                      | Normal Values                                      |
|----------------------------------------------|-----------------------------------------------------|
| Lymphopenia                                  | 20%–40%                                             |
| Elevated liver enzymes                       | ALT, 6–34 U/L; AST, 11–33 U/L                       |
| Elevated LDH levels                          | 120–141 U/L                                         |
| Elevated inflammatory markers (eg, CRP, ferritin) | CRP, 10 mg/L; ferritin, 20–250 ng/mL (men), 10–120 ng/mL (women) |
| Elevated d-dimer levels (>0.5 mcg/mL)        | d-dimer <231 DDU ng/mL                              |
| Elevated prothrombin time                    | 10.5–13.3 sec                                       |
| Elevated troponin levels                     | <0.03 ng/mL                                         |
| Elevated CPK levels                          | 10–120 mcg/L                                        |

Source.—Reference 23.

Note.—ALT = aminotransferase, AST = aspartate aminotransferase, CPK = creatinine phosphokinase, CRP = C-reactive protein, LDH = lactate dehydrogenase.

**Pulmonary Manifestations of COVID-19**

Respiratory illness is the most commonly associated manifestation of SARS-CoV-2. This is due to abundant ACE2 receptor expression in the lung parenchyma, specifically on the acinar side of lung epithelial cells (pneumocytes) within the alveolar spaces, allowing virus entry (Fig 1) (5). This correlates with the observation that the earliest lung injury is often seen in the distal airways (64). As discussed previously, alveolar damage is also attributable to the release of cytokines and chemokines that allow fluids to fill the pulmonary interstitium and acini, and the hypercoagulable state associated with COVID-19 that results in micro- and macrothrombosis of the pulmonary vasculature (65).

**Role of Imaging**

Chest radiography is typically the first-line imaging modality performed in patients with suspected COVID-19 infection. At patient admission, initial posterioranterior or anteroposterior (AP) chest radiographs are obtained, usually with the use of an intervening glass door to minimize exposure to the technologist (this technique
provides adequate quality for chest radiograph acquisition when compared with that of conventional methods) (66). Pulmonary consolidations and other pneumonia-related changes may be diagnosed when interpreting images obtained using this technique, as well as changes related to ARDS in patients who are critically ill. At early stages of disease and in mild cases, findings at chest radiography may be normal. Wong et al (64) found that initial chest radiography findings were abnormal in 69% of patients who required hospital admission, and in 80% of patients who had already been hospitalized (64).

**Chest Radiography and CT.**—The most commonly reported findings of COVID-19 at chest radiography include lung consolidation and ground-glass opacities (GGOs) (67). Reticular opacities may accompany areas of GGOs and can be well depicted on standard chest radiographs. Viral pneumonias, including COVID-19, typically produce lung opacities in more than one lobe. Additionally, evidence of multifocal air-space disease on chest radiographs can be indicative of COVID-19 pneumonia, most frequently in a lower lung distribution and bilateral (Fig 2). Peripheral lung involvement is one of the most specific features of this infection, although it may resemble other inflammatory processes with multifocal, patchy, or confluent distribution of findings, such as organizing pneumonia (Fig 3).

A pattern of diffuse lung opacities may also be seen with COVID-19 infection, as well as a number of other infectious and/or inflammatory processes, such as ARDS. During the disease course, lung opacities may rapidly evolve into a diffuse coalescent or consolidative pattern within 1–3 weeks after symptom onset, often peaking around 6–12 days after initial clinical presentation (Fig 3) (68,69). Pleural effusions, lung cavitation, and pneumothorax are rare findings in COVID-19 and, when depicted on chest radiographs, should raise suspicion for other potential causes (70–72).

In young and middle-aged patients, the extent of GGOs at chest radiography have been shown to correlate with the need for hospitalization and performing intubation. Toussie et al (73) reported that patients with GGOs depicted in at least two lung zones are more likely to require hospitalization and those with GGOs in three zones were more likely undergo intubation (73). On the basis of the pattern and distribution of the opacities and the presence or absence of certain clinical signs (such as obesity), the authors developed a chest radiography severity scoring system that could be used as a prognostic factor of outcomes in young adult patients with COVID-19 (Fig 3).

Advancements in new technologies such as artificial intelligence have allowed the utilization of automated assessment and tracking of COVID-19 pulmonary disease severity on chest radiographs. The results of this artificial intelligence–based longitudinal assessment could potentially be used for the prediction of patient prognosis (with respect to the likelihood of requiring intubation or death) (74).

Chest radiography and chest CT may be performed as adjuncts in cases of an initial negative RT-PCR test with persistent high clinical suspicion for disease. The American College of Radiology advises against using CT as a first-line tool in the diagnosis of COVID-19, recommending that it be used sparingly and reserved for symptomatic hospitalized patients with specific clinical indications, such as assessment of complications (75,76).

Chest radiography is a less sensitive modality for the detection of COVID-19 lung disease when compared with that CT, with a reported baseline chest radiography sensitivity of 69% (64). The
true sensitivity and specificity of CT for detection of COVID-19 remains relatively unknown. One study showed that radiologists identified cases of COVID-19 versus other viral pneumonias correctly 60%–83% of the time on the basis of typical CT features (77). However, the results of this study should be treated with caution, as the control and COVID-19–positive groups evaluated in this study came from two different institutions (the cases of COVID-19 came from China and control cases from the United States) (78).

**Pulmonary US.**—Pulmonary US is another imaging modality that has been shown to be useful in the evaluation of critically ill patients with COVID-19, as it can be performed at the bedside and allows detection of pneumonia (79). The most commonly depicted features of lung involvement at US include the presence of B-line artifacts, an irregular thickened pleura, and subpleural consolidations (Fig 4, Movies 1, 2) (80). B-line artifact distribution corresponds to subpleural thickened interlobular septa, as demonstrated at CT. B-line artifacts are vertically oriented, highly dynamic, and hyperechoic artifacts that originate from the pleura or from areas of consolidation that usually manifest in patients with alveolar-interstitial syndrome (80–82). These lines indicate accumulation of fluid in the pulmonary interstitial space (lung rockets) or alveoli (ground glass). When multiple, they are associated with pulmonary edema of cardiogenic, noncardiogenic, or mixed origin and are indicative of lung interstitial syndrome. B-line artifacts usually move with lung sliding. Absence of lung sliding should raise concern that the lung is not inflated or that there may be a pneumothorax.

**CT Pulmonary Angiography.**—Contrast-enhanced CT pulmonary angiography is performed to assess for possible PE in patients who develop acute dyspnea or acute deterioration of respiratory symptoms, or those in whom D-dimer markers are significantly elevated. The utilization of pulmonary scintigraphy (ventilation–perfusion scanning) in patients with suspected COVID-19 pneumonia should be limited, unless deemed essential for medical management. If ventilation–perfusion scanning is deemed necessary, the ventilatory phase of the examination should be eliminated and only the perfusion phase should be performed (83). Dual-energy CT has also been shown to be helpful for the evaluation of lung perfusion abnormalities (84).
Chest CT and Reporting.—The role of chest CT in COVID-19 is constantly evolving, with respect to clinical evaluation and treatment decisions. Whereas the 7th Chinese Novel Coronavirus Pneumonia Diagnosis and Treatment Plan incorporates CT into the criteria that clinically define COVID-19, the American College of Radiology and the Society of Thoracic Radiology, among others, advocate its use only in cases that require problem solving (75,85,86). The suitability of chest CT has also been assessed in various scenarios by the Fleischner Society, which deemed CT a major tool for diagnosis in patients with worsening symptoms or those in an environment that is resource constrained, with respect to RT-PCR testing availability (87).

The recent Radiological Society of North American expert consensus statement on reporting proposed standardized nomenclature and an imaging classification for COVID-19 pneumonia that involves four categories: typical appearance, indeterminate appearance, atypical appearance, and negative for pneumonia (Table 3) (78).

In an attempt to pursue standardized reporting, a COVID-19 Reporting and Data System (CORAD) based on a five-point scale of suspicion for

Table 3: Imaging Classification and CT Features of COVID-19 Pneumonia

| Imaging Classification | Rationale | CT Features |
|-----------------------|-----------|-------------|
| Typical appearance    | Commonly reported imaging features of greater specificity for COVID-19 pneumonia | Peripheral bilateral GGOs with or without consolidation or visible interlobular lines (“crazy-paving” pattern); Multifocal GGOs or rounded morphology with or without consolidation or visible interlobular lines (crazy-paving pattern); Reverse halo sign or other findings or organizing pneumonia (seen later in the disease) |
| Indeterminate appearance | Nonspecific imaging features of COVID-19 pneumonia | Absence of typical features AND the presence of the following features: multifocal, diffuse, perilobar, or unilateral GGO with or without consolidation lacking a specific distribution and that are nonrounded or nonperipheral; Few small GGOs, with a nonrounded and nonperipheral distribution |
| Atypical appearance | Uncommonly or not reported features of COVID-19 pneumonia | Absence of typical or indeterminate features AND the presence of the following features: isolated lobar or segmental consolidation without GGOs; discrete small nodules (centrilobular; “tree-in-bud” appearance); lung cavitation; smooth interlobular septal thickening with pleural effusion |

Source.—Adapted and reprinted under a CCBY 4.0 license from reference 78.
pulmonary involvement of COVID-19 at chest CT, was introduced (85). The CO-RAD score is based on the features depicted on nonenhanced chest CT images, with level of suspicion ranging from very low (CO-RADS 1) to very high (CO-RADS 5). Two additional categories were also created to account for a technically insufficient examination (CO-RADS 0) and RT-PCR–proven SARS-CoV-2 infection at the time of examination (CO-RADS 6).

**CT Findings.**—Similar to those at chest radiography, the most suspicious CT features for COVID-19 infection in the lungs include multifocal bilateral peripheral GGOs, with or without focal consolidations, in lung regions close to pleural surfaces, including the fissures (Figs 2, 5). Although subpleural involvement has been frequently documented, subpleural sparing may also be present (Fig 6) (85). There are two types
of GGOs that have been described: pure type and a mixed pattern, which is characterized by the presence of both GGOs and areas of consolidation (Fig 5). At CT, GGOs with or without consolidation are typically depicted in a peripheral, posterior, and diffuse or lower–lung zone distribution (67,78). Pure-type GGOs, the most commonly observed pattern, usually develop between days 0 and 4 after symptom onset, peaking at 6–13 days (69,88–90). Therefore, a negative chest CT examination should not be used to exclude the possibility of COVID-19, particularly early in the disease process (78).

Later in the disease course, the frequency of consolidation increases (Fig 5). In fact, Wang et al (89) noted that after symptom onset, the predominant imaging abnormality becomes a mixed pattern of GGOs, which typically peaks during days 12–17 of the illness and has been shown to be the second most prevalent pattern thereafter. As discussed previously, similar temporal changes have been observed on plain radiographs (Fig 3) (89).

Pulmonary vascular abnormalities such as vessel enlargement and regional mosaic perfusion patterns are also commonly found in COVID-19 pneumonia (84). Other more atypical or infrequent signs described in patients with COVID-19, such as the halo and reverse halo (or atoll) sign, usually manifest later in the disease course and are often absent at the time of symptom onset (Figs 7, 8) (78). The halo sign describes a nodule or mass surrounded by ground glass opacification, while the reverse halo (or atoll) sign is defined as a crescent or complete ring of consolidation that surrounds a focal area of GGO (Figs 7, 8) (91). Both appearances may be embedded within an area of consolidation. However, it is important to note that these findings are not specific, as they have been previously described in early stages of opportunistic invasive fungal infections in immunocompromised patients (eg, aspergillosis, mucormycosis), as well as in immunocompetent patients diagnosed with nonfungal endemic infections, cryptogenic organizing pneumonia, vasculitis, neoplasm, and inflammatory diseases (91).

Unifocal unilateral lesions are uncommon and found only in 2% of patients with COVID-19 (Fig 9) (92). The development of gelatinous mucus secretions may be responsible for lung collapse that can coexist with adjacent areas of consolidation. Contrast-enhanced CT aids in the differentiation of collapsed atelectatic lung from pneumonia by demonstrating parenchymal lung enhancement within atelectatic lung and absent or markedly diminished lung enhancement in the setting of pneumonia (Fig 10). Bronchial wall thickening was described in 10%–20% of patients with COVID-19 (Fig 11) (93). Pleural effusion, cavitation, pulmonary nodules, tree-in-bud opacities, and lymphadenopathy have not been reported in patients with COVID-19 and can be useful in differentiating COVID-19 pneumonia from other conditions (94).

In normal lung, subsegmental vessels are usually inconspicuous within the subpleural regions. However, it has been shown that many patients with COVID-19 exhibit tortuous and dilated distal vessels in the subpleural lung (84). These findings should not be confused with pulmonary vascular thickening (or thick vessel sign) within pulmonary opacities in COVID-19 pneumonia, which has been reported to range from 59% to 82% in patients with COVID-19 (77,95,96). Pulmonary vascular thickening is a nonspecific sign and can be seen in other conditions, including pulmonary hypertension, pulmonary veno-occlusive disease, hepatopulmonary syndrome, and portopulmonary hypertension (97).

Figure 6. GGOs and subpleural sparing in a 68-year-old man with COVID-19 and difficulty breathing. Axial contrast-enhanced CT image shows bilateral diffuse peripheral GGOs with subpleural sparing (arrows).

Figure 7. Halo sign in a 19-year-old man who presented with persistent fever and cough for 9 days and with positive test results for COVID-19. Axial nonenhanced CT chest image shows multifocal bilateral areas of mixed GGOs, with central nodular masslike opacities surrounded by ground-glass attenuation (arrows), a characteristic finding of a halo sign. Note that the opacities are located at the lung periphery.
Acute Respiratory Disease Syndrome

One of the most common respiratory complications of COVID-19 infection is ARDS (Fig 12). While ARDS is a clinical diagnosis that has a grading system based on the degree of hypoxia, imaging plays a supportive role in its diagnosis and management. It has been suggested that abnormal pulmonary vasoregulation may play a large role in patients with COVID-19 infection before the onset of radiologic or clinical manifestations that would suggest ARDS, and may be even more pronounced when ARDS does occur (84,98). The presence of disordered vasoregulation is supported by the frequency of pronounced dilatation of vasculature within regions of diseased lung, leading to significant ventilation and perfusion mismatches early in the disease. Perfusion abnormalities in the setting of COVID-19 pneumonia, most optimally assessed at dual-energy CT, may suggest an underlying vascular process.

Chest radiography and CT can aid in the identification of additional underlying causes of ARDS symptoms, such as superimposed bacterial pneumonia or congestive heart failure, although findings are frequently nonspecific. In the acute phase of ARDS, chest radiography may demonstrate bilateral airspace opacities with air bronchograms (Fig 13). Unless pulmonary edema is also present, septal lines and pleural effusions are not expected findings. In the acute exudative phase of ARDS, within the first week, CT demonstrates diffuse GGOs in a posterior and basal predominance, and a crazy-paving pattern may also be depicted (Fig 13). The crazy-paving appearance is thought to be attributable to superimposition of thick interlobular septa on GGOs and was detected in 36% of patients with COVID-19 (69). In the subsequent subacute phase of ARDS, consolidations may develop posteriorly or anteriorly if the patient is prone, with reversible bronchiectasis (Figs 11, 14). In the late phase of ARDS, more
than 2 weeks after onset, CT images can show signs of fibrosis, with architectural distortion, reticulation, and traction bronchiectasis (Figs 5, 13, 14) (99).

Patients admitted to the ICU with barotrauma as a result of intubation or as a complication of ARDS may develop pneumothoraces or pneumomediastinum, further complicating the pulmonary manifestations of COVID-19 infection (Figs 14–16). In fact, patients with COVID-19 who require mechanical ventilation were found to be at increased risk of barotrauma when compared with patients with ARDS alone and patients without COVID-19. Barotrauma was associated with a longer length of hospital stay and was an independent risk factor for death in patients with COVID-19 (100).

**Pulmonary Embolism**
PE is another complication of COVID-19 infection, described in further detail in the “Peripheral and Central Vascular Manifestations of COVID-19” section. In recently published studies, the incidence of PE in patients with COVID-19 who underwent pulmonary CT angiography was reported to be between 23% and 30%
Currently, there are conflicting results as to whether there is increased probability of PE in patients with COVID-19 who are receiving intensive care or require mechanical ventilation when compared with those who are not admitted to the ICU (50,102). A notable risk factor for the development of PE is obesity, with recent data showing that patients with a body mass index greater than 30 kg/m$^2$ are 2.7 times more likely to develop PE. Additionally, African American patients are at higher risk of developing PE when compared with other ethnic groups (102). With respect to the location and distribution of thrombi, PE is more commonly found in the segmental and lobar branches and less commonly in the central pulmonary arteries (Fig 17) (102).

Long-term effects of the disease and follow-up long-term imaging sequelae have not been well established at this point and are still under investigation. Organ-specific vascular manifestations and complications will be discussed in the corresponding part 2 article in a future issue of *RadioGraphics.*
Figure 14. Time course of lung changes in a 59-year-old man with COVID-19 pneumonia evaluated at chest radiography and CT over a 2-month period, which was complicated by development of a pneumothorax. (a–c) AP chest radiographs obtained at hospital admission (a), 4 days later (b), and 1 month later (c) show a peripheral patchy opacity in the left mid lung (oval in a) at the initial assessment, with substantial progression of lung disease on day 4 (b), with development of multiple bilateral peripheral areas of consolidation. The radiograph obtained 1 month later (c) shows interval improvement of the bilateral areas of consolidation and an increase in reticular opacities (dashed arrows in c), with the development of bronchial dilatation (solid arrow in c). Note that at this time the patient had undergone tracheostomy. (d, e) Axial (d) and coronal (e) contrast-enhanced chest CT images, obtained at the same time as c for worsening shortness of breath, show diffuse GGOs associated with superimposed interlobular reticulations, resulting in a crazy-paving pattern (dashed black arrows) and bronchial dilatation (black solid arrows in e). The findings were complicated by the presence of a moderate-sized anterior pneumothorax (white arrows), which was not well appreciated on the plain radiograph (c).
Peripheral and Central Vascular Manifestations of COVID-19

Pathophysiology of Vascular Thrombosis

There is growing evidence of coagulopathy related to COVID-19, which may predispose patients to both venous and arterial thromboembolism and result in deep venous thrombosis (DVT), PE, limb ischemia, stroke, and myocardial infarction (103–105). Although the pathogenesis and incidence of thrombotic complications are not clearly understood, coagulopathy has been noted to be a poor prognostic indicator and is associated with higher mortality (60,103,106,107).

The most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevated d-dimer and fibrinogen levels (108) and correlates with a parallel rise in inflammatory marker levels, including but not limited to levels of C-reactive protein, tumor necrosis factor-α, and various interleukins (Fig 18) (54,107–109).

Initial data have demonstrated that COVID-19–associated coagulopathy manifests with features of both sepsis-induced coagulopathy and thrombotic microangiopathy (54,107–109). Multiple factors, including inflammatory cytokine release, critical illness, platelet activation, and endothelial dysfunction, play a role. This is further evidenced by recent histologic data that have demonstrated diffuse alveolar damage, microthrombi formation, and occlusion of small pulmonary vessels (65). However, it is still uncertain whether COVID-19 has other unique characteristics that result in direct activation of coagulation.

As seen in other infections that result in sepsis-induced coagulopathy, the primary infection of COVID-19 initiates cellular injury and results in an inflammatory response, which includes production of inflammatory cytokines, endothelial activation, and recruitment of neutrophils and mononuclear cells. The activation of coagulation is a host immune response that contributes to the compartmentalization of pathogens in an attempt to prevent dissemination. However, endothelial cell dysfunction results in excess thrombin production and disrupted fibrinolysis, which results in a hypercoagulable state. Following cellular injury, tissue factor, which is a critical initiator of the extrinsic coagulation pathway, is expressed on macrophages, monocytes, and endothelial cells and plays a central role in the development of coagulopathy and disseminated intravascular coagulation. Additionally, fibrinolysis is suppressed in sepsis (110,111).

Compared with the typical pattern of sepsis-induced coagulopathy, patients with COVID-19...
Figure 17. Saddle embolus in a 52-year-old man who presented to the emergency department with hypoxia and tachycardia and received positive test results for COVID-19. (a–c) Axial chest CT angiographic images show a saddle embolus (arrows in a), extending into the lobar and segmental pulmonary artery branches bilaterally, and associated dilatation of the right ventricle, suggestive of right heart strain (arrow in b). Patchy peripheral GGOs on the right and a nodular area of consolidation (arrows in c) on the left are typical findings of COVID-19 pneumonia. (d) Gray-scale (left) and corresponding color Doppler (right) US images of the left femoral vein (FV) obtained in the transverse plane show a partially occlusive thrombus (arrows). The vein was not compressible at manual compression (not shown).

are diagnosed with less prominent thrombocytopenia (111). Additionally, prothrombin time and partial thromboplastin time remain near normal and fibrinogen levels are elevated until later in the disease process when they decrease and patients subsequently develop disseminated intravascular coagulation (57,107–109).

Additionally, authors of a recent study have suggested that a small subset of severe COVID-19 cases demonstrate complement-mediated microvascular injury and thrombosis, consistent with activation of the alternative pathway and lectin pathway cascades (112).

It is also important to note that hypoxia itself can stimulate thrombosis through an increase in blood viscosity and a hypoxia-inducible transcription factor–dependent signaling pathway. Additionally, ARDS may be a potential cause for hypoxic pulmonary vasoconstriction, pulmonary hypertension, and right ventricular failure (104).

Aside from hemostatic derangements, underlying comorbidities (cancer, obesity, etc) and immobility and the use of mechanical ventilation, central venous catheters, and extracorporeal circuits contribute to thrombotic risk. In addition, current investigational medications for treating COVID-19 may have adverse drug-drug interactions with antiplatelet agents and anticoagulation therapy (113).

To summarize, the pathophysiology of the hypercoagulable state found in association with COVID-19 disease is extremely complex and multifactorial in nature, with many varied factors playing a role in its occurrence (Fig 18).

It is important to note that the existing evidence is primarily derived from a few small retrospective analyses, and further evaluation with large prospective cohort studies must be conducted to better understand this illness.

Role of Imaging
Duplex US, MR angiography, and CT angiography, as well as MR and indirect or combined CT venography are the primary noninvasive modalities for the diagnosis of arterial and venous thrombosis and thromboembolism in patients
with COVID-19 (114,115). However, it is important to note that these disease processes may also be detected at routine contrast-enhanced CT performed in the portal venous phase, particularly when the main or large branch vessels are affected. Taking into consideration that many multiorgan and multisystem complications of COVID-19 are caused by or directly associated with vascular thrombotic events, careful assessment of the vasculature is essential in the evaluation of all imaging examinations performed in patients with COVID-19.

**Venous Thromboembolism**

The risk of venous thromboembolism (VTE), which is already greater in all critically ill patients, is higher in those with critical illness due to SARS-CoV-2 infection (116). An ever-increasing number of published studies have assessed the risk of VTE in patients with COVID-19, with reported incidences of DVT ranging from 25% to 49% (54,116–118). The incidence was found to be much higher if both symptomatic and asymptomatic patients were assessed and in patients with prolonged hospital stays in the ICU (cumulative incidence rates were as high as 59% at 21 days of hospitalization) (118). The wide range of reported incidences can be explained by the fact that VTE remains largely underdiagnosed in patients with severe COVID-19, as only symptomatic patients generally undergo imaging. This is in part due to the contagious nature of COVID-19, as its high transmissibility rate complicates the workup of patients with infection. In an attempt to minimize exposure to radiologic technologists and transport personnel, only symptomatic patients are typically eligible to undergo imaging, often using abbreviated protocols and portable machines that may result in a limited evaluation.

Additionally, the concern over shortages of personal protective equipment (PPE) influenced the number and types of examinations that were offered to this group of patients. Underdiagnosis of complications of VTE in patients with COVID-19 is a significant issue, as many of these patients who are severely ill already have ARDS and its complications (including hypoxic pulmonary vasoconstriction, pulmonary hypertension, and right ventricular failure), and further insult from a PE may be fatal. It is important to note that veins of any caliber may be affected, and therefore all vessels should be scrutinized for potential thrombus.

Elevated d-dimer levels, commonly found in patients with COVID-19, do not currently warrant routine investigation for acute VTE in the absence of clinical manifestations or other supporting information (119). However, in patients with high clinical suspicion for VTE, there should be a low threshold for ordering diagnostic tests to evaluate for DVT and/or PE.
The imaging examinations performed to diagnose DVT or PE in patients with COVID-19 may not be requested or performed, potentially owing to patient instability. Moreover, performing imaging examinations may be challenging in patients with severe ARDS who require prone positioning. Investigating for PE as well as lower and upper extremity DVT may not always be feasible owing to these clinical and positioning issues. Although deterioration of right ventricular function in this setting may be a critical finding that justifies the need for establishing a diagnosis of PE, it could also be argued that the prognosis of patients with ARDS who require prone positioning is so grave that investigation for an underlying VTE may not alter the clinical course. Preventive and therapeutic use of antithrombotic agents is helpful toward mitigating the occurrence thrombotic and hemorrhagic events in these high-risk patients (104).

Lower and upper extremity Doppler US is the first-line imaging modality for diagnosis of peripheral venous thrombosis and can be performed at the bedside. Occlusive and partially occlusive thrombi and their potential associations with central lines can be readily diagnosed (Figs 19–21). Noncompressible veins, echogenic clot, and minimal or absent flow within a distended vein are the US hallmarks of acute or subacute DVT (Figs 21–23). Superinfection may result in thrombophlebitis and can be diagnosed by the demonstration of hyperemia in the wall of an otherwise thrombotic vessel at color Doppler US. In cases of incomplete and/or inadequate thrombus evaluation or extension of thrombus into a more central vessel, CT and MR venography can be employed (Fig 24). The presence of a filling defect within a vessel, with or without occlusion, is the characteristic finding of venous thrombosis.
Figures 22, 23. (22) Superficial vein thrombosis in a 72-year-old woman hospitalized with COVID-19. Transverse gray-scale (left) and color Doppler (middle) US images without compression and gray-scale US image with compression (right) show an occlusive thrombus in the dilated basilic vein (black arrows). Note the absence of flow within the vein on the color Doppler US image (middle) and noncompressibility of the vein (left). The brachial veins (white arrows) are compressible (right) and demonstrate patency on the color Doppler US image (middle). (23) Extensive bilateral upper extremity DVT in a critically ill 77-year-old man with COVID-19 who developed bilateral upper extremity swelling, with markedly elevated d-dimer levels (31,447 ng/mL). (a, b) Sagittal color (a) and power (b) Doppler US images show absent flow in the distended vein, with echogenic material in the left subclavian vein (arrow in a) and the right axillary vein (arrows in b), compatible with bilateral occlusive thrombi. Additional occlusive and nonocclusive thrombi were also seen (not shown). (c) Gray-scale US images without (left) and with (right) compression show a thrombus (arrows) in the right cephalic vein, which demonstrates no vascular compression (arrows).

22.

23a. 23b.

23c.

Arterial Thrombosis
The authors of only a few studies to date have evaluated the frequency of peripheral arterial thrombosis in patients with COVID, with a reported incidence of 3.7% (116). The authors of a few reported cases of lower extremity arterial thrombosis have suggested a link between preexisting peripheral arterial disease and the development of arterial thromboembolism. It has been hypothesized that acute and progressive thrombosis may be attributable to a combination of the hyperinflammatory state induced by COVID-19 superimposed on a preexisting condition (120,121).

Doppler US and CT angiography of the extremity vessels are both instrumental in the evaluation of peripheral arterial thrombosis. At US, absence of flow within an arterial segment is diagnostic of an occlusive thrombus. Abnormal waveforms (stump waveforms), character-
ized by a low amplitude and high-resistance pattern with absence of diastolic flow, can aid in identification of a more distal occlusion. Alternatively, tardus parvus waveforms within more distally recanalized vessels are findings suggestive of a more proximal significant stenosis or occlusion (Fig 25). Reconstituted flow, sometimes with collateralization, may be depicted distal to an occlusion. Peripheral and central arterial thromboembolism may also be the result of atrial fibrillation.

CT angiography aids in the assessment of the extent of thrombosis and its potential complications such as ischemia to a related structure or organ. An abrupt cutoff of the affected vessel may be readily detected at CT angiography (Figs 25–28, Movie 3). The few reported cases (122) of peripheral arterial thromboembolism associated with COVID-19 have involved both upper and lower extremity arteries, and carotid and vertebral artery involvement have been described as well. The larger central arterial system may also be involved (eg, floating thrombi may be visualized in the aorta and aortic arch) (Fig 29) (122). It is important to keep in mind that COVID-19 can affect more than one organ or structure, and every organ and vessel should be scrutinized when assessing for complications (Figs 27–29).

It is also essential to recognize that patients with COVID-19 may develop thrombosis of various vascular systems, and there could be concomitant involvement of one or more venous or arterial vascular beds. Therefore, if evidence of thrombosis is detected, careful assessment of the entire imaged vascular system, as well as correlated organ or structure, is essential.

**Conclusion**

SARS-CoV-2 is a novel coronavirus that has rapidly resulted in a worldwide pandemic and has been the cause of extreme morbidity and mortality. It primarily affects the respiratory system but may also impact a multitude of other systems in the human body, resulting in multiorgan injury and, in some cases, failure. Imaging plays a significant role in the detection, diagnosis, and assessment of virus-induced injury, as well as its associated complications. A recognition and understanding of the pathophysiology of the virus and its effects on the immune system and coagulation is paramount toward improving radiologists’

---

**Figure 24.** Inferior vena cava (IVC) and peripheral deep vein thrombosis in a 78-year-old man with COVID-19 with leg swelling and abdominal pain. Sagittal (a) and axial (b) contrast-enhanced CT images show filling defects in the bilateral common femoral veins (solid arrows). Near complete occlusion of the IVC (solid arrows in a) to the level of an IVC filter (dashed arrow in a) was present. Note the renal transplant (arrowhead in a). Both central and peripheral venous thrombosis were not depicted at prior imaging examinations (not shown).
Figure 25. Popliteal and posterior tibial artery thrombosis in a 58-year-old woman with COVID-19 in the ICU. (a, b) Sagittal color (a) and spectral (b) Doppler US images show an echogenic heterogeneous thrombus (white arrows) distending the right popliteal artery. The characteristic knocking or “stump-thump” waveform with absence of diastolic flow (black arrows in b) and low amplitude (yellow circle in b) imply the presence of occlusion just distal to the area of interrogation. (c) Sagittal power Doppler US image shows no flow in the occluded right posterior tibial artery (black arrows). (d) Corresponding sagittal CT angiographic reconstruction shows abrupt cutoff of the popliteal artery by a thrombus (solid arrow). Note the opacified popliteal artery (Rt POP A) proximal to the thrombus (dashed arrow). The patient also had a liver infarct and bowel ischemia (not shown).

Figure 26. Popliteal artery occlusion in a severely ill 65-year-old man with COVID-19 with bilateral diminished dorsalis pedis pulses. Coronal three-dimensional volume-rendered run-off CT angiographic image shows abrupt cutoff (arrows) of the bilateral popliteal arteries (PA), compatible with bilateral occlusion. Note that distally run-off calf arteries have been reconstituted through collateral arteries. R LE = right lower extremity, L LE = left lower extremity.

ability to accurately identify key imaging findings and promptly recognize possible complications, specifically those affecting the pulmonary and vascular systems, thereby minimizing the number of diagnostic misses and misinterpretations.

Appropriate application of the described chest radiography and CT scoring systems in the evaluation of lung involvement, including automated assessment, may increase the consistency of reported findings and aid in risk stratification, as well as offer prognostic information. Owing to the complexity of the viral pathophysiology and its targeting of multiple organ systems, the
Figure 27. Brachial artery thrombosis and renal infarct in a 51-year-old man who presented to the emergency department with acute left upper extremity pain and numbness. The patient had a 2-week history of cough and fever and was confirmed to be COVID-19 positive. (a) Coronal left upper extremity CT angiographic image shows an abrupt segmental occlusion (arrow) of the distal left brachial artery, indicative of peripheral arterial thromboembolization. The left subclavian and axillary arteries were otherwise unremarkable, with good opacification of the arteries. (b) Coronal three-dimensional maximum intensity projection shows abrupt cutoff (arrow) of the left brachial artery. (c, d) Axial chest CT angiographic images show the typical appearance of lung changes in COVID-19 pneumonia (arrows in c). Note the incidentally found sharp well-defined area of nonenhancement in the partially imaged upper pole of the right kidney, a finding indicative of a renal infarct (arrows in d).

Figure 28. Common carotid artery (CCA) occlusion in a 56-year-old woman with neurologic deficits who had been hospitalized with COVID-19. (a, b) Coronal three-dimensional maximum intensity projection reformatted image (a) and axial CT angiographic image (b) of the head and neck show an abrupt cutoff at the origin of the CCA (black arrow in a). Note the absence of opacification of the right CCA, as well as internal and external carotid arteries (arrows in b). The left carotid vasculature is well opacified with intravenous contrast material (white arrow in a). (c) Axial nonenhanced head CT image shows wedge-shaped areas of hypodensity (arrows) in a watershed distribution, consistent with acute infarcts related to carotid occlusion.
recognition of one complication should prompt intense scrutiny for others, particularly if the patient is critically ill. A thorough knowledge of diagnostic imaging hallmarks, atypical imaging features, multisystem manifestations, and evolution of imaging findings is essential to optimize patient care.

Acknowledgments.—The authors thank Christine O. (Cooky) Menias, MD, for her valuable guidance and recommendations; Misra Nilanjana, MD, Northwell Health, and Henry Douglas for their help with images; and Alexandria Brackett for the assistance with literature searches and references.

References
1. COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/. Accessed August 1, 2020.
2. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008—The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(suppl 1):1–203 [Published correction appears in BJOG 2015;122(5):e1.]
3. Wang T, Du Z, Zhu F, et al. Comorbidities and multiorgan injuries in the treatment of COVID-19. Lancet 2020;395(10228):e52.
4. Mahajan A, Hirsch JA. Novel Coronavirus: What Neuroradiologists as Citizens of the World Need to Know. AJNR Am J Neuroradiol 2020;41(4):552–554.
RNA-seq data analysis on the receptor ACE2 expression
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell betacoronaviruses. Nat Microbiol 2020;5(4):562–569.

Letko M, Marzi A, Munster V. Functional assessment of cell Prolonged Viral RNA Shedding in Patients with Coronavirus
Xu K, Chen Y, Yuan J, et al. Factors Associated With severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. Lancet Infect Dis 2020;20(6):656–657.

Zheng S, Fan J, Yu F. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443.

Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Respir Med 2020;8(5):475–481 [Published correction appears in Lancet Respir Med 2020;8(5):e26].

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(12):1229.

Goyal P, Choi JJ, Pinho LG, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020;382(24):2372–2374.

Kolifarhood G, Aghaali M, Mozafar Saadati H, et al. Epidemiological and Clinical Aspects of COVID-19: a Narrative Review. Arch Acad Emerg Med 2020;8(1):e1.

Xiao AT, Feng XN, Zou B. Profile of PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa460. Published online April 19, 2020. Accessed June 1, 2020.

Illinois Department of Public Health. COVID-19 Statistics. https://www.dph.illinois.gov/covid19/covid19-statistics. Accessed April 9, 2020.

Mehta MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in
Update—Venous Thrombosis and Hypercoagulability in the E188.

Toussie D, Voutsinas N, Finkelstein M, et al. Clinical and Chest Radiography Features to Differentiate Patient Outcomes In Young and Middle Age Adults with COVID-19. Radiology 2020. doi: 10.1148/radiol.202021754. Published online May 14, 2020. Accessed May 1, 2020.

Li MD, Arun NT, Gidwani M, et al. Automated assessment of COVID-19 pulmonary disease severity on chest radiographs using convolutional Siamese neural networks. medRxiv [preprint] https://doi.org/10.1101/2020.05.20.20108159. Posted May 26, 2020. Accessed May 1, 2020.

American College of Radiology. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID-19-Infection. Updated March 22, 2020. Accessed March 12, 2020.

Stempniak M. CT should not be used as first-line tool against coronavirus, ACR warns following pandemic declaration. Radiology Business. https://www.radiologybusiness.com/topics/care-delivery/ct-scan-coronavirus-chest-x-ray-radiology-covid-19. Published March 11, 2020. Accessed March 11, 2020.

Bai I, Hsieh B, Xiong Z, et al. Performance of Radiologists in Differentiating COVID-19 from Non–COVID-19 Viral Pneumonia at Chest CT. Radiology 2020;296(2):E46–E54.

Sipos B, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA—Secondary Publication. J Thorac Imaging 2020;35(4):219–227.

Soldati G, Smargiassi A, Inchogoro R, et al. Is There a Role for Lung Ultrasound During the COVID-19 Pandemic? J Ultrasound Med 2020;39(7):1459–1462.

Volpicelli G, Mussa A, Garofalo G, et al. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. J Emerg Med 2006;24(6):689–696.

Efremov SM, Kuzkov VV, For EV, et al. Lung Ultrasonography and Cardiac Surgery: A Narrative Review. J Cardiothorac Vasc Anesth 2020. doi: 10.1053/j.jvca.2020.01.032. Published online January 23, 2020. Accessed May 1, 2020.

Kooraki S, Hosseiny M, Myers L, Gholamrezaeehad A. Re: Ventilation-Perfusion Scans During the Coronavirus Disease 2019 (COVID-19) Outbreak. J Am Coll Radiol 2020;17(6):698–699.

Som A, Lang M, Little B. Pulmonary Vascular Pathology in Covid-19. N Engl J Med 2020. doi: 10.1056/NEJMm2022068. Published online July 17, 2020. Accessed August 1, 2020.

Prokop M, van Everdingen W, van Rees Vellinga T, et al. CO-RADS: A Categoric CT Assessment Scheme for Patients Suspected of Having COVID-19: Definition and Evaluation. Radiology 2020;296(2):E97–E104.

Hope MD, Raptis CA, Shah A, Hammer MM, Henry TS; six signatories. A role for CT in COVID-19? What data really tell us so far. Lancet 2020;395(10231):1189–1190.

Rubin GD, Ryerson CJ, Haramati LB, et al. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. Chest 2020;158(1):106–116.

Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020;295(3):715–721.

Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology 2020;296(2):E35–E64.
This journal-based SA-CME activity has been approved for AMA PRA Category 1 Credit™. See rsna.org/learning-center-rg.